You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)附属收购Bayer位于德国的制造工厂的设施资产
格隆汇 01-16 08:40

格隆汇1月16日丨药明生物(02269.HK)公布,公司间接全资附属公司WuXi Biologics Germany与Bayer于1月16日订立资产购买协议,据此,WuXi Biologics Germany将向Bayer购买位于德国利华古逊的生物药制剂cGMP灌装制造工厂的设施资产,以持续扩大集团的产能,进一步满足全球对生物药生产不断增长的需求。

公告显示,为确保收购后制造工厂营运顺畅,WuXi Biologics Germany亦与Bayer分别就制造工厂房屋的长期分租及若干相关过渡服务订立分租协议及过渡服务协议。

据悉,同资产购买协议,WuXi Biologics Germany自Bayer处分租用于制造工厂的D201大楼的区域及相关储存及管理区域,整体楼面总面积约为8,768平方米。

公司表示,集团将获得优质生物药制剂生产能力,以继续支持其最近于中国及海外的强劲增长。交易符合公司整体发展计划,进一步扩大集团制造能力及使其更多元化,并为其全球合作伙伴提供优质的供应链网络,以通过其"药明生物提供全球双厂生产"策略惠及全球病患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account